Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11235MR)

This product GTTS-WQ11235MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11235MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6785MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ687MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ11935MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ4365MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ1924MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ3802MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ11901MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ7617MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW